A paper published this week in Nature Communications by researchers at Imperial College London makes the case that the microbial protein sector’s repeated commercial failures are not primarily a technology problem, and that resolving them will require coordinated action on consumer psychology, regulation, and market infrastructure simultaneously.
The paper, co-authored by Rima Gnaim, Hakimi Kassim, Lisa Neidhardt, Thomas Gassler, and Rodrigo Ledesma-Amaro, traces a pattern stretching back decades: technically viable ventures collapsing not because the science failed, but because the surrounding conditions did.
Early industrial programmes in the 1970s and 1980s were undone by high operating costs and easing food shortages. More recently, Swedish mycoprotein company Mycorena is cited as an example of a promising platform that lost commercial momentum under the combined pressure of high R&D intensity, complex scale-up, and constrained capital access.
The disgust problem
Survey data from the UK, Germany, and Romania found that 47.1% of respondents exhibited neophobia toward fungal protein, frequently associating it with spoilage or excessive processing, with disgust responses significantly lowering purchase intent. The authors argue that regulatory clearance alone is insufficient to drive uptake, and that familiarity has to be actively built through repeated exposure and sensory reformulation.
The paper also cautions against treating microbial protein as a single category. Products based on well-established organisms such as Saccharomyces cerevisiae face a materially different consumer and regulatory environment from those derived from less familiar sources such as marine bacteria or newly isolated fungi, and the authors argue they should be communicated and regulated accordingly.
Capital structure as the chokepoint
For companies that clear the consumer hurdle, production economics remain the next constraint. The paper identifies greenfield facility construction as particularly high-risk, and notes that financing increasingly favours platforms that can retrofit existing fermentation infrastructure. Fragmented intellectual property landscapes add further cost burdens, particularly for smaller manufacturers.
The authors recommend shared pilot infrastructure, public co-funding, and institutional procurement through schools and hospitals as routes to creating stable baseline demand. Fiscal measures such as reduced VAT are proposed to close the price gap with conventional proteins.
Quorn, derived from Fusarium venenatum and on sale since 1985, is the paper’s primary example of mainstream normalisation achieved through sustained communication and retail presence rather than scientific credentials alone. Microbial proteins currently represent 8.2% of the alternative protein market by sales, against 88.9% for plant-based products. The sector was valued at approximately $1.7 billion in 2024 and is projected to reach roughly $5 billion by 2034.
